Anti-tumor activity of Ea-4-peptide of pro-IGF-I
Compositions of pro-IFG-I E-peptides for the treatment and amelioration of tumor-producing diseases, and methods for their utilization.
1. A method of inhibiting the proliferation of a malignant cell, comprising administering to the malignant cell in vitro a nucleic acid containing a gene encoding a recombinant trout Insulin-like Growth Factor (IGF-1) Ea2 or Ea4 peptide.
2. The method of claim 1 , wherein the trout IGF-1 Ea2 or Ea4 peptide is selected from the group consisting of: a trout IGF-I Ea2 or Ea4 peptide homolog, and a trout IGF-I Ea2 or Ea4-peptide fusion protein.
3. The method of claim 2 , wherein the trout IGF-1 Ea2 or Ea4E-peptide is from a rainbow trout.
4. The method of claim 2 , wherein the trout IGF-1 Ea2 or Ea4-peptide is selected from the group consisting of: Ea-2 domain peptide of SEQ ID NO:2, and Ea-4 domain peptide of SEQ ID NO:4.
5. The method of claim 4 , wherein the nucleic acid encoding the trout IGF-1 Ea2 or Ea4-peptide is administered in a pharmaceutical composition.
6. A method for reducing the invasiveness of malignant cells, comprising administering to the malignant cells in vitro a nucleic acid containing a gene encoding a recombinant trout IGF-I Ea2 or Ea4 peptide.
7. The method of claim 6 , wherein the trout IGF-1 Ea2 or Ea4-peptide is selected from the group consisting of: a trout IGF-1 Ea2 or Ea4-domain peptide homolog, and a trout IGF-1 Ea2 or Ea4-domain peptide fusion protein.
8. The method of claim 7 , wherein the trout IGF-1 Ea2 or Ea4-peptide is an E-domain peptide of a rainbow trout.
9. The method of claim 8 , wherein the trout IGF-1 Ea2 or Ea4-peptide is selected from the group consisting of: Ea-2 domain peptide of SEQ ID NO:2, and Ea-4 domain peptide of SEQ ID NO:4.
10. The method of claim 9 , wherein the nucleic acid encoding the trout IGF-1 Ea2 or Ea4-peptide is administered in a pharmaceutical composition.